Replies to post #65330 on Biotech Values

[genisi]

Re: “missing” patients in the SPRINT trial

I'm sure there's a reasonable explanation for the difference between n=226 patients in the no lead-in 48-week arm, reported at EASL and the n=210 patients in this arm, reported in SGP's PR. Moreover, whether it's a mistake or if these patients are to be found, data from this arm can not be of great importance, as you pointed out.